MHT use in over-65s still beneficial: study
Oestrogen monotherapy in over-65s was associated with a 19% mortality risk reduction, researchers say.
Use of menopausal hormone therapy beyond age 65 is associated with risk reductions in mortality as well as specific cancers and cardiovascular diseases, according to a study published online 9 April in Menopause.
Dr Seo H Baik (PhD), from the US National Institutes of Health in Bethesda, Maryland, and colleagues examined the effects of different preparations of menopausal hormone therapy (MHT) on all-cause mortality, five cancers, six cardiovascular diseases, and dementia using data for 10 million senior Medicare women.
